Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone

References

• Weiden PJ, Young AH, Buckley PF. The art and science of switching of antipsychotic medications, part 1. J Clin Psychiatry. 2006;67(11):e15
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, ; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, ; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4): 611–622
   PubMed Web of Science ®Google Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160–161
   Google Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68( suppl 4):34–39
   PubMed Web of Science ®Google Scholar
• Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68( suppl 6):10–13
   PubMedGoogle Scholar
• Scheifler PL, Weiden PJ. Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications. Postgrad Med. 2006;Spec No:45–53
   Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25( suppl 2):S12–S21
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Cañas F, Gallhofer B, . Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opin Pharmacother. 2010;11(13):2199–2220
   PubMed Web of Science ®Google Scholar
• Edlinger M, Baumgartner S, Eltanaihi-Furtmúller N, Hummer M, Fleischhacker. Switching between second-generation antipsychotics: why and how? CNS Drugs. 2005;19(1):27–42
   Google Scholar
• Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580–588
   Web of Science ®Google Scholar
• Simpson GM, O'Gorman CJ, Loebel A, Yang R. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr. 2008;13(10):898–905
   Google Scholar
• Alptekin K, Hafez J, Brook S, . Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229–238
   Google Scholar
• Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;23(4):216–222
   PubMed Web of Science ®Google Scholar
• Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):997–1000
   Google Scholar
• Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121–125
   PubMed Web of Science ®Google Scholar
• Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry. 2009:10(4 pt 3):710–718
   Google Scholar
• Montes JM, Rodriguez JL, Balbo E, . Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383–388
   PubMedGoogle Scholar
• Bartkó G, Trixler M, Bitter I, Degrell I, Fúredi J, Faludi G; Ziprasidonra Váltást Vizsgáló Munkacsoport. Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics [in Hungarian]. Neuropsychopharmacol Hung. 2006;8(4): 201–209
   Google Scholar
• Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595–600
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Longterm changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985–994
   PubMed Web of Science ®Google Scholar
• Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res. 2007;94(1–3):99–106
   Google Scholar
• Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9(5):357–364
   Web of Science ®Google Scholar
• Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66(2–3): 101–113
   Google Scholar
• Grootens KP, van Veelen NM, Sitskoorn MM, . Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. Eur Neuropsychopharmacol. 2010;20(12):907–912
   Google Scholar
• Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc (2003). 2007;47(3):373–378
   Google Scholar
• Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799–812
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Clinical Global Impression (CGI). In: Guy W, ed. ECDEU assessment manual in psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1970:217–222
   Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L, . The extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7:233
   Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212( suppl):11–19
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health Education and Welfare Publication (ADM) 76–338. Rockville, MD: National Institute for Mental Health; 1976
   Google Scholar
• IMS Health Inc. International Medical Systems National Disease and Therapeutic Index. Plymouth Meeting, PA: IMS Health; January 2001–December 2004
   Google Scholar
• Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64( suppl 19):6–12
   Web of Science ®Google Scholar
• Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477–489
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68( suppl 4):34–39
   PubMed Web of Science ®Google Scholar
• Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69( suppl 1):4–17
   Web of Science ®Google Scholar
• . Zeldox Capsule. Summary of product characteristics. Pfizer AB, 191 90 Sollentuna, Sweden. Revised September 4, 2009
   Google Scholar
• Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192–208
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686–693
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255–262
   PubMed Web of Science ®Google Scholar
• Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667
   PubMed Web of Science ®Google Scholar
• Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int J Psychopharmacol. 1995;10( suppl 3):S133–S138
   PubMed Web of Science ®Google Scholar
• Reitan R. Validity of the Trial Making Test as an indicator of organic brain disease. Percept Psychomotor Skills. 1958;8:271–276
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, Inc; 1994
   Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;163;(22):39–44
   Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
   PubMed Web of Science ®Google Scholar
• . Geodon capsules and injections for intramuscular use [package insert]. LAB-0273–16.0. New York, NY: Pfizer Inc. Revised November 2009. http://media.pfizer.com/files/products/uspi_geodon.pdf. Accessed September 24, 2010
   Google Scholar
• Strom BL, Eng SM, Faich G, . Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (ZODIAC) [published online ahead of print November 1, 2010]. Am J Psychiatry
   Google Scholar
• Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26(8):739–748
   PubMed Web of Science ®Google Scholar
• Gandelman K, Alderman JA, Glue P, . The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58–62
   Google Scholar
• Bowden CL. Treatment strategies for bipolar depression. J Clin Psychiatry. 2010;71(5):e10
   Google Scholar
• Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry. 2007;68( suppl 6):14–23
   Google Scholar
• . Zyprexa [package insert]. ZY49M. Indianapolis, IN: Eli Lilly and Co. Updated January 15, 2010. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed September 24, 2010
   Google Scholar
• Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211–216
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;113(1):112–121. Erratum in: Schizophr Res. 2010;121(1–3):281
   PubMed Web of Science ®Google Scholar